null Petr Kavan, MD, PhD

Associate Investigator, RI-MUHC

Cancer Research Program

Associate Professor, Gerald Bronfman Department of Oncology, Faculty of Medicine and Health Sciences, McGill University

Department of Dentistry, Division of Hematology, MUHC



Adolescent and Young Adult Oncology (AYA) • colorectal cancer • brain tumor • hepatocellular carcinoma (HCC)

Research Focus

My research focuses on gastro-intestinal, hepatobiliary, and neurological cancers.

Selected Publications

Click on Pubmed to see my current publications list

  • Bevacizumab Plus Radiotherapy/Temozolomide for newly diagnosed Glioblastoma (AVAglio). Olivier L, Chinot MD, …..Petr Kavan, ….and Timothy Cloughesy. NEJM 2014

  • Bevacizumab use for recurrent high-grade glioma at McGill University Hospital. Sahebjam S, Garoufalis E, Guiot MC, Muanza T, Del Maestro R, Petrecca K, Sharma R, Kavan P,. Can J Neurol Sci 2013 Mar; 40(2): 241-6

  • Randomized phase 2 study of pegylated SN-38 (EZN-2208) or irinotecan plus cetuximab in patients with advanced colorectal cancer. Garrett CR, Bekaii-Saab TS, Ryan T, Fisher GA, Clive S, Kavan P, Shacham-Shmueli E, Buchbinder A, Goldberg RM. Cancer. 2013 Sep 16. doi: 10.1002/cncr.28358.

  • Bevacizumab-based therapy for colorectal cancer: experience from a large Canadian cohort at the Jewish General Hospital between 2004 and 2009. Bouganim N, Mamo A, Wasserman DW, Batist G, Metrakos P, Chaudhury P, Hassanain M, Kavan P. Curr Oncol. 2013 Oct;20(5):247-51. doi: 10.3747/co.20.1370.

  • A real-life experience using panitumumab in chemo-refractory metastatic colorectal cancer patients: a retrospective analysis at the Jewish General Hospital, 2009-2012. Mamo A, Nogueira MC, Batist G, Palumbo M, Panasci L, Ferrario C, Chaudhury P, Metrakos P, Kavan P. Curr Oncol. 2013 Apr;20(2):e107-12. doi: 10.3747/co.20.1271.